Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and Serplulimab in First-Line nccRCC
NCT05831891Phase 2Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- May 2023
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, serplulimab in non-clear cell renal cell carcinoma (nccRCC), sponsored by Renji Hospital. Started May 2023; status: active, not recruiting.
02
Drugs
fruquintinibserplulimab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT05831891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831891.